HealthyNCT04625088
Identification of Biometric Marker(s) Capable of Detecting Early Prediabetes: Clinical Trial 1
A study testing Standardized liquid test meal and Atropine + Standardized liquid test meal in people with Healthy, run by SciMar Ltd. at 1 site in Canada.
Trial summary
The proposed clinical trial is a controlled study of n=24 healthy adult individuals tested in both the Meal-Induced Insulin Sensitization (MIS) state and, following atropine blockade, Absence of Meal-Induced Insulin Sensitization (AMIS) state to differentiate the postprandial glycemia, insulinemia, triglyceride and… Read more about this study
- Who is it for?
- Ages 20 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Standardized liquid test meal and Atropine + Standardized liquid test meal
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteCanada
- Study dates
- 1 Mar 2021to 6 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy (absence of disease)
- Not on any prescribed medications
- Male and female (in follicular phase)
- 20-40 years of age
- Normal BMI range (18.5-24.9)
- Able to understand and communicate in English
Show all 14Show fewer
- Comfortable having blood drawn
- Willing to provide urine and blood samples
- Normal urinalysis, Complete Blood Count (CBC) and blood chemistry laboratory test results
- Willingness to undergo bioimpedance testing, handgrip dynamometry (strength) testing, and pulmonary function test (spirometry).
- Willingness to undergo atropine administration
- Willingness to fast for 12 hours prior to the screening and testing days
- Willingness to undergo Electrocardiogram (ECG) and Heart Rate Variability (HRV) testing
- Willingness to use non-hormonal birth control methods throughout the study duration
Who cannot join
- Glaucoma, Pyloric Stenosis
- Obstructive Uropathy, Urinary Incontinence
- Diabetes, Cardiovascular Disease, including Heart Murmurs
- Diagnosed or with history (last 6 months) and receiving pharma or professional therapy for Psychological/Psychiatric issues
- Inflammatory conditions, including IBD
- Subject on any hormone treatment, including thyroid hormone
Show all 13Show fewer
- Subject on any steroid therapy including cortisol, or any anti-inflammatory agent
- Sensitivity to anti-cholinergic drugs
- Allergic or have sensitivities to rubbing alcohol during blood draw
- Allergy/sensitivity to any component of the standardized test meal (dextrose, lecithin, soy protein)
- Pregnant women, women of child-bearing potential not willing to use barrier method contraceptives, women trying to get pregnant, and breastfeeding women, women using hormonal birth control
- Whole blood donation (50-499 ml of whole blood) within 30 days, and more than 499 ml of whole blood 56 days prior to test visit 1. Participants should not donate whole blood for the duration of the trial, and for 30 days following the end of the trial
- Blood pressure greater than 140/90 mmHg and heart rate greater than or equal to 80 beats per minute
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Identification of Biometric Marker(s) Capable of Detecting Early Prediabetes: Clinical Trial 1: Antagonism of Hepatic Muscarinic Receptors Attenuates the Postprandial Actions of Hepatic Insulin Sensitizing Substance (HISS)
The proposed clinical trial is a controlled study of n=24 healthy adult individuals tested in both the Meal-Induced Insulin Sensitization (MIS) state and, following atropine blockade, Absence of Meal-Induced Insulin Sensitization (AMIS) state to differentiate the postprandial glycemia, insulinemia, triglyceride and Hepatic Insulin Sensitizing Substance (HISS) levels in the two states.
The purpose of this study is the identification and development of biometric markers which incorporate the actions and interplay between insulin and HISS. Overall, the study aims to:
Read more
- Utilize a standardized test meal to detect one of the earliest pathologies present during the development of insulin resistance, pre-diabetes and obesity.
- Compare the control (HISS positive) and post-atropine (HISS negative) tests with the acute consequences of absence of MIS (AMIS) being graphically shown over 4 hours of postprandial nutrient partitioning, tracking the full metabolomic dynamic pattern.
- To establish values for potential indices (bio-impedance, hand-grip strength, spirometry) in young, fit, lean individuals. These values will be used as baselines for comparative analysis in future clinical trials employing individuals with various degrees of insulin resistance to full Type 2 Diabetes.
- Demonstrate that these biometric markers can differentiate between the HISS positive and HISS negative post-meal state with the future aim of using the biomarkers for the detection of early prediabetes.
The study will involve 4 study visits: Visit 1 - Prescreening; Visit 2 - Screening; Visit 3 - Liquid test meal administration and postprandial blood collection; Visit 4 - Atropine administration + Liquid test meal administration and postprandial blood collection.
- Conditions
- Healthy
- Being tested
- Standardized liquid test meal, Atropine + Standardized liquid test meal
- Keywords
- Glucose; Insulin; Prediabetes
- Medical subject headings
- Insulin Resistance, Prediabetic State
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standardized liquid test mealOther
During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.
Atropine + Standardized liquid test mealDrug
During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
| Study group | Role | What they receive |
|---|---|---|
| Standardized liquid test meal | Experimental | Not described Receives: Other: Standardized liquid test meal |
| Atropine + Standardized liquid Test meal | Experimental | Not described Receives: Drug: Atropine + Standardized liquid test meal |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time course change in serum glucose
Time course and curve analysis of serum glucose response after the test meal administration with and without atropine pre-treatment.
Measured: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course change in serum insulin
Time course and curve analysis of serum insulin response after the test meal administration with and without atropine pre-treatment
Measured: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course change in serum triglycerides
Time course and curve analysis of serum triglycerides response after the test meal administration with and without atropine pre-treatment
Measured: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course change in plasma HISS levels
Time course and curve analysis of plasma HISS response after the test meal administration with and without atropine pre-treatment
Measured: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Secondary outcomes (4)
Time course change in serum free fatty acids
Time course and curve analysis of serum free fatty acid response after the test meal administration with and without atropine pre-treatment
Measured: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course change in plasma lactate
Time course and curve analysis of plasma lactate response after the test meal administration with and without atropine pre-treatment
Measured: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time frame fasted HOMA-IR (Molar Units)
Time frame HOMA-IR, calculated using the formula: fasting insulin (mIU/L) X fasting glucose (mmol/L)
Measured: Control: Baseline fasted Test: 15 mins post atropine
Time course change in Meal Induced Glycemia (MIG) scores (Molar Units)
Time course and curve analysis of Meal Induced Glycemia (MIG) scores response after the test meal administration with and without atropine pre-treatment. MIG is calculated using the formula: MIG = (post meal insulin mIU/L X post meal glucose mmol/L) minus (fasted insulin mIU/L X fasted glucose mmol/L). Higher score equates to a worse (unhealthy) outcome
Measured: Control: Every 30 minutes up to 4 hours after test meal administration; Test: Every 30 minutes up to 4 hours after test meal administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2020
- Study start1 Mar 2021
- Primary completion6 Aug 2021
- Study completion6 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- SciMar Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Source Nutraceutical, Inc.
- Responsible party
- Sponsor
- Investigators
- Vanu Ramprasath, PhD, Principal investigator, Source Nutraceutical, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04625088
- Sponsor's protocol ID
- CT-001
- Status last verified
- Feb 2022
- First submitted
- 29 Oct 2020
- Last updated
- 3 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Identification of Biometric Marker(s) Capable of Detecting Early Prediabetes: Clinical Trial 1: Antagonism of Hepatic Muscarinic Receptors Attenuates the Postprandial Actions of Hepatic Insulin Sensitizing Substance (HISS)
- ClinicalTrials.gov ID
- NCT04625088
- Acronym / sponsor ID
- CT-001
- Conditions
- Healthy
- Keywords
- Glucose; Insulin; Prediabetes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- SciMar Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Source Nutraceutical, Inc.
- Study start
- 1 Mar 2021 (actual)
- Primary completion
- 6 Aug 2021 (actual)
- Study completion
- 6 Aug 2021 (actual)
- First posted
- 12 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed clinical trial is a controlled study of n=24 healthy adult individuals tested in both the Meal-Induced Insulin Sensitization (MIS) state and, following atropine blockade, Absence of Meal-Induced Insulin Sensitization (AMIS) state to differentiate the postprandial glycemia, insulinemia, triglyceride and Hepatic Insulin Sensitizing Substance (HISS) levels in the two states.
The purpose of this study is the identification and development of biometric markers which incorporate the actions and interplay between insulin and HISS. Overall, the study aims to:
- Utilize a standardized test meal to detect one of the earliest pathologies present during the development of insulin resistance, pre-diabetes and obesity.
- Compare the control (HISS positive) and post-atropine (HISS negative) tests with the acute consequences of absence of MIS (AMIS) being graphically shown over 4 hours of postprandial nutrient partitioning, tracking the full metabolomic dynamic pattern.
- To establish values for potential indices (bio-impedance, hand-grip strength, spirometry) in young, fit, lean individuals. These values will be used as baselines for comparative analysis in future clinical trials employing individuals with various degrees of insulin resistance to full Type 2 Diabetes.
- Demonstrate that these biometric markers can differentiate between the HISS positive and HISS negative post-meal state with the future aim of using the biomarkers for the detection of early prediabetes.
The study will involve 4 study visits: Visit 1 - Prescreening; Visit 2 - Screening; Visit 3 - Liquid test meal administration and postprandial blood collection; Visit 4 - Atropine administration + Liquid test meal administration and postprandial blood collection.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standardized liquid test meal | Experimental | Other: Standardized liquid test meal |
| Atropine + Standardized liquid Test meal | Experimental | Drug: Atropine + Standardized liquid test meal |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- Healthy (absence of disease)
- Not on any prescribed medications
- Male and female (in follicular phase)
- 20-40 years of age
- Normal BMI range (18.5-24.9)
Key exclusion criteria (13 listed)
- Glaucoma, Pyloric Stenosis
- Obstructive Uropathy, Urinary Incontinence
- Diabetes, Cardiovascular Disease, including Heart Murmurs
- Diagnosed or with history (last 6 months) and receiving pharma or professional therapy for Psychological/Psychiatric issues
- Inflammatory conditions, including IBD
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standardized liquid test mealDuring this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal. | Other | Standardized liquid test meal |
| Atropine + Standardized liquid test mealDuring this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal. | Drug | Atropine + Standardized liquid Test meal |
Primary outcome
Time course change in serum glucose
Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course and curve analysis of serum glucose response after the test meal administration with and without atropine pre-treatment.
Time course change in serum insulin
Time frame: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course and curve analysis of serum insulin response after the test meal administration with and without atropine pre-treatment
Time course change in serum triglycerides
Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course and curve analysis of serum triglycerides response after the test meal administration with and without atropine pre-treatment
Time course change in plasma HISS levels
Time frame: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course and curve analysis of plasma HISS response after the test meal administration with and without atropine pre-treatment
4 secondary outcomes
Time course change in serum free fatty acids
Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time course change in plasma lactate
Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration
Time frame fasted HOMA-IR (Molar Units)
Time frame: Control: Baseline fasted Test: 15 mins post atropine
Time course change in Meal Induced Glycemia (MIG) scores (Molar Units)
Time frame: Control: Every 30 minutes up to 4 hours after test meal administration; Test: Every 30 minutes up to 4 hours after test meal administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2022.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
Brain Mapping, Healthy Volunteer
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
Recruiting
Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness
Improving Healthy Food Access in Food Insecurity Populations in Normal and Emergency Situations
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
Recruiting
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
Healthy Volunteer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vanu Ramprasath, PhD principal investigator
Source Nutraceutical, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standardized liquid test meal and Atropine + Standardized liquid test meal in people with Healthy, run by SciMar Ltd. at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time course change in serum glucose (time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2022; AzTrials last refreshed its copy on 8 Nov 2026.